FedCircuitBlog

Next week is argument week at the Federal Circuit, and four cases slated to be argued attracted amicus briefs. A patent case, Biogen MA v. EMD Serono, Inc., drew interest from Bayer Healthcare Pharmaceuticals on the issue of invalidity of a patent “for the use of recombinant IFN-β ‘polypeptides’ to treat various diseases.” Here is our argument preview.

As a reminder, once a month we provide an update on activity in patent cases pending before panels of the Federal Circuit where the cases involve at least one amicus brief. We keep track of these patent cases in the “Other Cases” section of our blog. (There we also highlight non-patent cases that attract amicus brief, but only once those cases have been scheduled for oral argument.) Today, with respect to patent cases, we highlight one new opinion, a recent oral argument, and three upcoming oral arguments.